Exclusive Summary

• Breakthrough MOA for "Undruggable" Target: Utilizes a novel dual-targeting synthetic lethality approach against c-Myc and a tissue-specific transcription factor (PXXX)/DDR pathway, overcoming toxicity issues common in c-Myc inhibitors.
• High-Value Differentiated Indications: Specifically designed for Gynecological Cancers (e.g., Ovarian Cancer) and Triple-Negative Breast Cancer (TNBC), addressing massive unmet medical needs.
• Strong Pre-clinical Profile: Oral small molecule demonstrating significant tumor regression and excellent tolerability in xenograft models, with a strategic plan for potential regulatory Accelerated Approval.

Asset Materials

Contact Us for Full Materials